Fuji introduces Synapse Simplicity
For low-volume medical centers that need networking, Synapse Simplicity is the answer, according to its developer, Fujifilm Medical Systems USA. Synapse Simplicity is an economical version of the company's Synapse PACS. The product, unveiled at the HIMSS
For low-volume medical centers that need networking, Synapse Simplicity is the answer, according to its developer, Fujifilm Medical Systems USA. Synapse Simplicity is an economical version of the company's Synapse PACS. The product, unveiled at the HIMSS meeting, can handle 60,000 procedures annually. A complete package configuration could include diagnostic or clinical workstations, a multifunctional PACS server, DVD high-speed robotic archiving, and professional installation and integration services. Because Simplicity uses the same hardware and software components as Fuji's community and enterprise PACS offerings, the system can expand to meet changing facility needs. The new package joins two other Fuji products designed specifically for low-volume imaging facilities, SmartCR and the DryPix 1000 dry imager.
2/28/01, Issue # 1504, page 4.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
